We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Salt Chambers Helpful for Asthma Patients

By HospiMedica staff writers
Posted on 20 Jun 2006
A new study finds that breathing salt dust for 40 minutes a day can reduce bronchial hyper-responsiveness in patients with asthma.

Researchers from South Karelia Central Hospital (Lappeenranta, Finland) evaluated the effects of salt-chamber treatment in 32 patients with persistent asthma who exhibited bronchial hyper-responsiveness to histamine challenge, despite inhaled steroid treatment. More...
The patients were randomly assigned to two weeks of treatment in a constructed halo chamber,” designed to simulate the microclimate of salt mines. Patients received daily 40-minute sessions for five days a week, with a salt generator either blowing salt dust into the chamber or running without salt being fed in.

After two weeks, the median provocative dose of histamine caused a 15% drop in forced expiratory volume (FEV1) in one second, a significant increase in the active treatment group, whereas patients who spent time in the chamber with minimal salt concentrations experienced declines in FEV1. Bronchial hyper-responsiveness decreased by at least one doubling dose in nine patients (56%) in the active group compared with only two patients (17%) in the placebo group. Six patients in the active group (38%) no longer responded to histamine after treatment compared with none of the patients in the placebo group. By two months after completion of the salt chamber treatment, four of 13 patients in the active group and one of nine patients in the placebo group were unresponsive to histamine challenge. The results were reported in the May 2006 issue of Allergy.

Natural salt caves and salt mines have been used for years as complementary medicine for treating asthmatic patients in various parts of Europe and Asia.

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.